Symbiance AI Announces revolutionary product to automate the writing of Clinical Study Report (CSR) and other scientific documents.
PRINCETON, N.J., Aug. 4, 2021 /PRNewswire/ -- Symbiance AI, today announced the launch of its Artificial Intelligence (AI) powered product ZYLiQ which accelerates medical writing. This launch reflects Symbiance's growth ambitions and passion to answer certain challenges within clinical research by leveraging the power of AI.
- PRINCETON, N.J., Aug. 4, 2021 /PRNewswire/ --Symbiance AI, today announced the launch of its Artificial Intelligence (AI) powered product ZYLiQ which accelerates medical writing.
- This launch reflects Symbiance's growth ambitions and passion to answer certain challenges within clinical research by leveraging the power of AI.
- ZYLiQ is a revolutionary product that automates 60-70% of CSR writing, adhering to regulatory and ICH E3 guidelines, reduction in the number of reviews, and ultimately saving time & cost.
- Symbiance AI is a division of Symbiance Inc., a global CRO founded in 1990 with extensive clinical research expertise and global reach.